Evidence Tier III · Mechanism mapped, mostly preclinical

AOD-9604: A Research Overview

Modified HGH fragment 176-191 studied for lipolysis without GH/IGF-1 effects; human tolerability data but inconsistent efficacy.

AOD-9604 is a growth-hormone-derived peptide studied for a specific and appealing idea: capturing the fat-metabolizing part of growth hormone without its growth-promoting effects. The concept is elegant, and the preclinical work is real, but the honest center of the AOD-9604 story is that its human evidence, while it exists, has been inconsistent on the outcome that matters most — weight loss. An honest overview presents the mechanism and the genuine (if mixed) human data without overselling either.

This overview summarizes what the published literature reports about AOD-9604 — its structure, mechanism, evidence, and status. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What AOD-9604 Is

AOD-9604 (sometimes called “Advanced/Anti-Obesity Drug 9604”) is a synthetic peptide based on the C-terminal fragment of human growth hormone — specifically amino acids 176-191 — with an added tyrosine residue at the N-terminus that improves stability (CAS 66004-57-7 refers to the parent fragment). It was developed by Metabolic Pharmaceuticals, originating from work by Professor Frank Ng at Monash University in Australia in the 1990s (AOD-9604 structure and origin). A useful distinction: AOD-9604 is the modified, better-studied molecule; the unmodified “HGH Fragment 176-191” is related but not identical and has not been studied in humans the way AOD-9604 has (AOD-9604 vs. unmodified fragment).

Mechanism — Lipolysis Without the GH Effects

The design rationale is that growth hormone has separable growth-promoting (somatogenic) and fat-metabolizing (lipolytic) activities, and the 176-191 region carries much of the lipolytic activity. AOD-9604 is studied for promoting lipolysis (fat breakdown) and inhibiting lipogenesis (new fat formation), with mechanistic work pointing to involvement of beta-3 adrenergic receptor pathways and direct effects on adipose tissue — reportedly without raising blood glucose, causing insulin resistance, or driving IGF-1 production the way full growth hormone does (lipolytic mechanism and beta-3/adipose involvement). That GH-independent selectivity is the compound’s defining feature.

The Evidence Base — Preclinical Plus Mixed Human Data

In obese-mouse and ex vivo adipose models, AOD-9604 reduced weight gain and increased fat oxidation/lipolysis, with beta-3-adrenergic involvement suggested (preclinical obese-mouse / adipose findings). Unlike many compounds in this library, AOD-9604 also reached human trials — but here the honest point is decisive: human trials have mainly reported safety/tolerability, while weight-loss efficacy signals were inconsistent across studies and protocols (human-trial safety with inconsistent weight outcomes). So the picture is a plausible mechanism and reassuring tolerability, but human efficacy has not been consistently demonstrated.

Modified HGH fragment 176-191 (with N-terminal tyrosine); GH-derived but designed to avoid GH/IGF-1 effects.
Studied for lipolysis/anti-lipogenesis via beta-3 adrenergic and direct adipose actions (preclinical).
Reached human trials; tolerability reported, but weight-loss efficacy inconsistent; not approved.

Safety and Status

The status below reflects mid-2026 and may change; verify before relying on it. AOD-9604 is not an FDA-approved drug for weight loss or any indication; it has been examined in the supplement/research space and has received some food-ingredient-related regulatory attention in the past, but that is not drug approval. In trials, it was generally well tolerated. Research-grade material is sold for laboratory use only and, by its labeling, is not for human consumption. As an HGH-derived agent it may also be relevant to anti-doping considerations in sport.

Why AOD-9604 Draws Research Interest

AOD-9604 is an interesting test of whether growth hormone’s fat-metabolizing activity can be isolated from its other effects — mechanistically appealing and, unusually, supported by human safety data. The accurate framing is a GH-derived lipolytic peptide with a plausible mechanism, genuine preclinical support, human tolerability data, but inconsistent human efficacy, and no approval.

For deeper reading, the cited literature is the best starting point. AOD-9604 sits near the growth hormone axis and metabolic research compounds — see the tesamorelin and ipamorelin overviews. The wider class is collected in our peptide research library.

Frequently Asked Questions

What exactly is AOD-9604, and where did it come from?

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone — specifically amino acids 176 through 191 — with a tyrosine residue added at the N-terminus to improve stability. It is sometimes called 'Advanced/Anti-Obesity Drug 9604.' The compound was developed by Metabolic Pharmaceuticals, originating from research by Professor Frank Ng at Monash University in Australia in the 1990s. It is worth noting that AOD-9604 is not the same molecule as the unmodified 'HGH Fragment 176-191' — the two are related but distinct, and the human research that exists was conducted on AOD-9604 specifically, not the unmodified fragment.